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Five percent of all tumors occur in the head and neck 
region and approximately half of those occur speciﬁcally 
in the oral cavity. Among these malignancies, the most 
frequently encountered is undoubtedly the Oral Squamous 
Cell Carcinoma (OSCC) accounting for more than 90% of 
cases (1) . Its prevalence increases with age and with abuse 
of risk factors such as alcohol and tobacco (1). Oral cancer 
shows well-established multi-phasic and multi-factorial 
dynamics. It is well known that the multi-step model of 
oral carcinogenesis requires the step-wise transition from 
pre-malignant conditions to the tumor phenotype (2). A 
variety of genomic alterations accumulates and potentiates 
this transition gradually promoting the progression from 
normal mucosa, to dysplasia, until to carcinoma in situ 
and advanced cancer (2). 
Despite great ﬁnancial and scientiﬁc efforts, the 
percentage of long-term survival in patients with OSCC 
is still low, especially when a deﬁnitive surgery is not 
applicable, because low efﬁcacy of anticancer drugs. 
Thus, a better understanding of the molecular proﬁle 
of oral carcinogenetic processes should facilitate the 
development of more efﬁcient targeted therapies (3).
The steroid hormones play an important role in 
expression of genes involved in a wide variety of 
biological and neoplastic processes. In particular, the role 
of the Estrogen Receptor (ER) and estrogen-regulated 
protein in various normal and pathological tissues (such as 
breast cancer) has been widely studied (4) and hormonal 
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Sexual hormones play an important role in expression of genes involved in a wide variety of biological and 
neoplastic processes. The information on Estrogen Receptors (ER) expression in non-target tissues is very few 
and, in particular, the studies in head and neck tumors are still controversial. Recent studies analyzed the role of 
Tamoxifen (TAM) on Oral Squamous Cell Carcinoma (OSCC) lines in relation to the presence/absence of ER. The 
purpose of the present study was to evaluate the expression of sexual hormones receptors mRNAs, in particular 
Estrogen Receptor alpha (ERα) and Androgen Receptor (AR) mRNA in OSCC tissues. The study group comprised 
20 samples of OSCC, harvested from 20 otherwise healthy subjects (14 males and 6 females, mean age 58.2y, 
range 38-74). The control group was formed by 20 samples of normal mucosa harvested around the margins of 
the specimens (at least 1 cm from the lesion margins). Estrogens Receptor alpha (Era) and Androgen Receptor 
(AR) mRNA expressions were analyzed by RT-PCR carried out on total RNAs extracted from both cancerous 
and healthy tissues. Obtained data were evaluated by Shapiro-Walk normality test and compared by Student’s 
t test. Results with p<0.05 were considered statistically signiﬁcant.  AR transcripts were less expressed in OSCC 
specimens than in healthy tissues, while levels of ERα transcripts signiﬁcantly increased in tumor samples. These 
preliminary data show different expression patterns of AR and ERα mRNAs in malignant tissues of oral mucosa 
and could suggest an involvement of these sexual hormones in oral cancer. 
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RT-PCR, cloning and sequencing
First strand cDNA was synthesized using 3 μg total RNA, 
40 ng random exameric primer (Promega Corp., Madison, 
USA) and 200 U Superscript III (Invitrogen, Paisley, UK) 
in a total volume of 20 μl according to the manufacturer’s 
instructions (Invitrogen, Paisley, UK). Then, 3 μl of this 
cDNA template were used for the PCR (ﬁnal volume 25 μl) 
with 1.5 mM MgCl2, 1x PCR buffer (10 mM Tris-HCl, pH 
9.0, 50 mM KCl), 0.2 mM dNTP, 2.0 U Taq DNA polymerase 
(Promega Corp., Madison, USA) and 5 pmol of speciﬁc 
oligonucleotide primers for ERα and AR (see Table I). The 
same cDNA template (1.5 μl) was also used, as control, to 
amplify an appropriate region of GAPDH cDNA with speciﬁc 
oligonucleotide primers (Table I). The ampliﬁcation products 
for ERα (40 cycles: 94°C for 30”, 60°C for 30”, 72°C for 
45”), for AR (40 cycles: 94°C for 30”, 59°C for 30”, 72°C 
for 45”) and for GAPDH (30 cycles: 94°C for 30”, 60°C for 
30”, 72°C for 45”) were electrophoresed on 1.2% agarose 
gel in 1xTAE buffer and the quantization was performed 
by densitometry analysis using GELDOC1.00-UV System 
(BIORAD, Hercules, CA). The ampliﬁcation products were 
puriﬁed by a QIAGEN gel extraction kit (QIAGEN, Hilden, 
Germany) and were cloned into the pGEM-T Easy vector 
according to the manufacturer’s instructions. The inserts were 
sequenced and the nucleotide sequences were compared to the 
human sequences in the NCBI gene bank database to verify the 
speciﬁcity of the ampliﬁed products. 
Statistics
The data were expressed as means ± SD. The Gaussian 
distribution of continuous variables was assessed by the 
Shapiro-Wilk normality test and the statistical analysis was 
performed by the Student’t-test. Probability levels <0.05 were 
considered statistically signiﬁcant.
RESULTS
The expression levels of sexual hormone receptors 
transcripts were studied in OSCC specimens and samples 
of normal tissue adjacent to the lesion. RT-PCR analysis, 
carried out on total RNA with the speciﬁc oligonucleotide 
primers (Table I), has revealed the presence of the 
expected cDNA fragments for ERα (520 bp, Fig.1A-upper 
panel) and AR (534 bp, Fig.2A-upper panel); in control 
PCR, using speciﬁc primers for GAPDH, the expected 
462 bp band was also obtained (Fig.1A and 2A-lower 
panels). The ERα and AR fragments were eluted from 
gel, cloned and sequenced to conﬁrm the speciﬁcity of the 
PCR products. 
In Fig.1B and 2B we report the averages of the 
relative densitometric amounts of ERα or AR cDNAs, 
respectively, versus GAPDH cDNA, obtained on ten 
specimens and performed in duplicate. This analysis 
demonstrated that, in OSCC specimens, expressions of 
ERα and AR transcripts are respectively higher (Fig.1B) 
and lower (Fig.2B) than in normal tissues.
treatment (i.e. non-steroidal Selective Estrogen Receptor 
Modulator - SERM) has been proposed and successively 
applied. Therefore, the information on ER expression 
in non-target tissues are very few and, in particular, the 
studies in head and neck tumors are still controversial 
(5). To date, only immunohistochemical studies have 
investigated on the presence of steroid receptors in head 
and neck tumors (6). In fact, ER and Progesterone Receptor 
(PgR) proteins in salivary gland adenoid cystic carcinoma 
have been identiﬁed and the possible use of endocrine 
therapy as a modality of treatment has been suggested (7). 
Several studies analyze the role of Tamoxifen (an estrogen 
antagonist) on OSCC lines in relation to the presence/
absence of ER (8). In this increasing and suggestive 
scenario, the purpose of the present study was to evaluate 
the expression of sexual hormones receptors mRNAs, in 
particular Estrogen Receptor alpha (ERα) and Androgen 
Receptor (AR) mRNA in OSCC tissues.
MATERIALS AND METHODS
Tissues
Twenty patients affected by OSCC, not previously treated 
with chemotherapy and/or irradiation, were consecutively 
selected for this study. All patients were otherwise healthy; 14 
were male and 6 female, with a mean age of 58.2 years (range 
38-74). For each patient, two samples of surgical specimen 
were taken: neoplastic and normal tissue (harvested around the 
margins of the specimen at least 1 cm from the lesion margins). 
In all cases, the classiﬁcation of the tissue was made at the time 
of surgery by the surgeon (C.G.). Histopathologic examinations 
were carried out routinely on the samples and the margins were 
found to be tumor-free. Finally, the samples were quickly frozen 
by immersion in liquid nitrogen and were stored at –80°C until 
RNA extraction.
This protocol was approved by an Institutional Review 
Board and patients gave informed consent.
 
RNA extraction
Total RNA from OSCC and healthy tissues was extracted with 
Trizol reagent (Invitrogen, Paisley, UK), a mono-phasic solution 
of phenol and guanidine isothiocyanate, an improvement to the 
single-step RNA isolation method developed by Chomczynski 
and Sacchi (9). Tissues were homogenized in 1 ml of Trizol 
reagent; after addition of chloroform for the extraction and 
precipitation with isopropyl alcohol, the resulting RNA pellet 
was washed with 70% ethanol and dissolved in sterile water.
Oligonucleotide primers 
Speciﬁc oligonucleotide primers were designed on mRNA 
sequences, from NCBI gene bank database, of human androgen 
receptor (AR, accession No: NM_000044), human estrogen 
receptor alpha (ERα accession No: NM_000125) and human 
glyceraldeide-3-phosphate dehydrogenase (GAPDH, accession 
NM_002046) to amplify respectively 534, 520 and 462 bp of the 
corresponding coding region (Table I).
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DISCUSSION
The common treatment modalities of OSCC are 
surgery and/or radiotherapy-chemotherapy. However, 
the survival rate of the patients has not been improved 
by the management with these current therapies. (3). The 
expressions of sexual hormone receptors in some tumors 
suggest a role for these molecules in their pathogenesis and 
furnish a possibility of a non-invasive and complementary 
treatment. It has widely been demonstrated that breast and 
prostate cancers often express hormone receptors and can 
be controlled by hormone manipulation (10).
With regard to Head and Neck (HN) district, previous 
studies evaluated the presence of steroid hormone 
receptors in HNSCC, mainly with immunohistochemical 
or radioimmunological analysis, reporting controversial 
results. A majority of these investigations, conducted 
principally in relation to laryngeal carcinoma (being the 
larynx a target organ for androgenic steroids), suggest 
the hormonal therapy as useful adjunctive strategy of 
treatment (6).
Here we investigate the presence and the expression 
levels of sexual steroid receptors, in particular ERα and 
AR transcripts, in ten OSCC using RT-PCR analysis. Our 
data indicate that ERα mRNA is more expressed in the 
OSCC than in control tissues while opposite results have 
been obtained for AR, in fact, it is less expressed in the 
OSCC than in the control tissues. 
A recent study reported a cross-talking between 
estrogen receptor and EGFR and suggested that both the 
estrogen receptor and EGFR pathways together contribute 
to HNSCC and provided a rationale for potentially 
targeting these pathways in combination as a new 
treatment strategy for head and neck cancer (11). Our data 
also suggest that a OSCC (presence of ERα) may respond 
to hormonal stimulation. 
On other hand our results do not support the hypothesis 
of a inhibitory effect of estrogen in the growth of cancer 
cells, as suggested for the esophageal cancer in order to 
explain the mystery of male predominance (12).
 Actually, there are no scientiﬁc evidences for the 
AR role in oral carcinogenesis. In 1994 Nehse and 
Tunn measured Androgen (AR) and progesterone (PgR) 
receptors expression in 18 samples of normal oral mucosa 
and squamous cell carcinoma of the ﬂoor of the mouth or 
the tongue (13). There was a signiﬁcant difference from 
Primer Sense Antisense
Erα (520 bp) 5’-GATGATGGGCTTACTGACCAAC-3’ 5’GATGTGGGAGAGGATGAGGAG-3’
AR (534 bp) 5’-ATTGAGCCAGGAGTGGTGTGT-3’ 5’-CTTGAGCAGGATGTGGGATT-3’
GAPDH (462 bp) 5’-GTGGATATTGTTGCCATCAATGA-3’ 5’-GATGGCATGGACTGTGGTCA-3’
Table I. Primer sequences used for PCR analysis
Fig. 1. (A) Electrophoretic analysis of ERα (upper panel) and 
GAPDH (lower panel) transcripts ampliﬁed by RT-PCR. The 
results shown are relative to two specimens. C=carcinoma, 
N=normal, nc=negative control. (B) Pattern of relative 
densitometric amounts shown as Era : GAPDH ratios. (a vs. 
b=p<0.05)
Fig. 2. (A) Electrophoretic analysis of AR (upper panel) and 
GAPDH (lower panel) transcripts ampliﬁed by RT-PCR. The 
results shown are relative to two specimens. C=carcinoma, 
N=normal, nc=negative control. (B) Pattern of relative 
densitometric amounts shown as AR : GAPDH ratios. (a vs. 
b=p<0.05)
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the androgen receptor level in the normal mucosa (13). 
Recently Rosa et al. demonstrated that [CAG]n repeat 
<20 is associated with a more aggressive head and neck 
cancer subset, in particular in male patients with ﬁrst-
degree family history and oral cavity or oropharyngeal 
cancers (14) and we know that AR expression is reduced 
in cells with longer AR CAG repeat alleles (15). The 
explanation of this correlation is probably that the length 
of the AR polyglutamine stretch could modify the AR 
transactivation activity by affecting the associations of the 
AR with its co-activators in different cell types (16). 
In conclusion present data indicate that sex hormones 
may inﬂuence the normal-dysplasia-cancer evolution of 
the oral mucosa, and could contribute to understanding 
the molecular pathways of chemotherapy for OSCC 
through the use of speciﬁc antagonists (i.e. SERM). 
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